Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells $3,265,606.76 in Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Declan Doogan sold 121,942 shares of Biohaven Pharmaceutical stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $26.78, for a total transaction of $3,265,606.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Declan Doogan also recently made the following trade(s):

  • On Wednesday, January 10th, Declan Doogan sold 40,362 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $27.69, for a total transaction of $1,117,623.78.

Biohaven Pharmaceutical Holding Co Ltd (BHVN) opened at $26.44 on Friday. Biohaven Pharmaceutical Holding Co Ltd has a 52-week low of $17.00 and a 52-week high of $39.51. The stock has a market cap of $1,100.00 and a price-to-earnings ratio of -5.07.

Hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc bought a new position in Biohaven Pharmaceutical during the third quarter worth $119,000. Nationwide Fund Advisors bought a new position in Biohaven Pharmaceutical during the third quarter worth $214,000. American International Group Inc. bought a new position in Biohaven Pharmaceutical during the third quarter worth $251,000. State of Wisconsin Investment Board bought a new position in Biohaven Pharmaceutical during the third quarter worth $262,000. Finally, Susquehanna International Group LLP bought a new position in Biohaven Pharmaceutical during the third quarter worth $302,000. 47.76% of the stock is currently owned by institutional investors and hedge funds.

BHVN has been the topic of a number of recent analyst reports. Morgan Stanley reissued an “overweight” rating and issued a $38.00 price target (down previously from $47.00) on shares of Biohaven Pharmaceutical in a research report on Tuesday, October 3rd. Zacks Investment Research raised shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Monday, December 4th. Piper Jaffray Companies set a $48.00 price target on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Monday, December 11th. Needham & Company LLC dropped their price target on shares of Biohaven Pharmaceutical from $43.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday, October 3rd. Finally, Canaccord Genuity initiated coverage on shares of Biohaven Pharmaceutical in a research report on Friday, December 15th. They issued a “buy” rating and a $30.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $36.14.

ILLEGAL ACTIVITY NOTICE: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells $3,265,606.76 in Stock” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2018/01/14/biohaven-pharmaceutical-holding-co-ltd-bhvn-director-sells-3265606-76-in-stock.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit